Serum creatinine as a perioperative biomarker: A challenge for perioperative management and an opportunity for the Cardiothoracic Surgery Trials Network  by Augoustides, John G.
EXPERT REVIEWSerum creatinine as a perioperative biomarker: A challenge for
perioperative management and an opportunity for the
Cardiothoracic Surgery Trials NetworkJohn G. Augoustides, MD, FASE, FAHADespite recent advances, coronary artery bypass grafting
(CABG) is still associated with adverse outcomes in
patients with renal dysfunction both in the short term and
in the long term, even when it is subclinical.1-3 Serum
biomarkers, such as serum creatinine, enhance the
identification of high-risk patients and thus may further fa-
cilitate targeting of interventions to optimize outcome after
CABG.4 In fact, elevated serum creatinine has already been
integrated into standard cardiac surgical risk calculators,
such as the Society of Thoracic Surgeons PROM score
and the EuroSCORE.
Recent evidence, however, has demonstrated that serum
creatinine is not always a sensitive and specific test for renal
dysfunction in patients undergoing CABG, because it de-
pends on factors beyond renal function, such as age, sex,
and muscle mass.5 Calculation of glomerular filtration
rate by accepted methods, such as the Cockroft-Gault for-
mula or the Modification of Diet in Renal Disease equa-
tions, appears to be superior to plain serum creatinine in
the identification of renal dysfunction and the prediction
of adverse outcomes after CABG.5,6 In fact, the detection
of renal injury in patients undergoing CABG is further
enhanced by looking beyond both serum creatinine and
calculated creatinine clearance. Recent evidence points to
preoperative proteinuria as an independent predictor for
adverse outcomes after CABG, including acute renal
dysfunction, dialysis, and prolonged stays both in the
intensive care unit and in the hospital.7
This ongoing clinical refinement of serum creatinine as
an outcome biomarker for CABG resembles recent progress
in the world of myocardial biomarkers. The clinical utility
of creatine kinase MB has been further enhanced by such
biomarkers as troponin and heart-type fatty acid–binding
protein.8-9
Despite these limitations of serum creatinine as an out-
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The Journal of Thoracic and CaThe study by Pan and colleagues10 in this issue adds even
more weight to the predictive importance of perioperative
serum creatinine for complications after CABG. In this
study, Pan and colleagues10 have demonstrated that mortal-
ity after CABG is predicted by subclinical increases in peri-
operative serum creatinine, increases that are insufficient to
meet standard definitions of acute kidney injury. This obser-
vation suggests that subclinical increases in serum creati-
nine early after CABG might constitute an indication for
prompt clinical intervention.
Given that serum creatinine and the derived creatinine
clearance are sensitive risk predictors after CABG, the chal-
lenge for perioperative management is the selection of ef-
fective therapies in this setting to optimize clinical
outcome by protecting the vital organs at risk. Recent con-
sensus and evidence suggest a diverse menu of candidate in-
terventions that merit further study in the treatment of
patients after CABG who are considered to be at high risk
on the basis of their serum creatinine profiles.11 This
menu of perioperative clinical research opportunities in-
cludes but is not limited to statin therapy, intensive platelet
blockade, moderate glucose control, atrial natriuretic pep-
tide, levosimendan, and remote ischemic conditioning.11-15
Despite this progress, a revision of the role of biomarkers
in predicting perioperative injury is still required for delin-
eation not only of more sensitive levels of existing bio-
markers but also of novel biomarkers for different organs.
Existing biomarkers could be further refined by systematic
comparisons between existing biomarkers and searches for
synergistic combinations.8 As an example, troponin and
B-type natriuretic peptide could be compared against each
other and in combination as outcome biomarkers after
CABG.16 Novel biomarkers are also in development. As
an example, a recent expert commentary in the Journal
has highlighted the promise of neutrophil gelatinase–asso-
ciated lipocalin for detection of cardiac surgery–associated
acute kidney injury.17
The menu of research opportunities developed in this ed-
itorial showcases a major opportunity for a clinical research
consortium such as the Cardiothoracic Surgery Trials Net-
work.18,19 Multiple challenges in performing multicenter
trials in cardiac surgery persist, such as lack of an
infrastructure, lack of a dedicated research culture,
screening, enrollment, clinical equipoise, and collaboration
across specialties.18,19 The imperative is to overcome these
obstacles to stay abreast with developments in patient care
because the times are changing.20rdiovascular Surgery c Volume 143, Number 3 523
Expert Review AugoustidesIn conclusion, Pan and colleagues10 are to be congratu-
lated for highlighting the outcome utility of subclinical in-
creases in serum creatinine after CABG. It is anticipated
that future trials will take the leap to refine biomarkers
and define perioperative interventions for mitigation of ad-
verse clinical outcomes in adult cardiac surgical patients
identified as being at high risk by such biomarkers as serum
creatinine.References
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